Cusabio Technology LLC's Avatar

Cusabio Technology LLC

@cusabio.bsky.social

Cusabio is a biotechnology enterprise specialized in the R&D, production and sales of Elisa kit, protein and antibodies.

19 Followers  |  150 Following  |  7 Posts  |  Joined: 03.01.2025  |  1.733

Latest posts by cusabio.bsky.social on Bluesky

Preview
CD24: A Key Element in the EXO-CD24 Technique for Combating COVID-19- CUSABIO EXO-CD24 is a therapeutic technique for Combating COVID-19. If EXO-CD24 proves to be safe and effective, CD24 will largely participate in the COVID-19 therapy. What is CD24 and how might it work in CO...

๐Ÿฆ  #CD24 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed on immune cells, epithelial cells, and tumor cells. It plays a key role in immune regulation, particularly in dampening excessive immune responses. Read more: bit.ly/3Dc2M1O

28.02.2025 01:06 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM) - Cusabio GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) has emerged as a promising therapeutic target, garnering significant attention in the field of oncology and immunotherapy. Particularly in ...

Amgenโ€™s multi-million dollar investment in GPRC5D-targeted CAR-T therapy highlights its potential to reshape MM treatment. As research advances, could GPRC5D be the future of immunotherapy? Read more: bit.ly/42l1Emy

22.01.2025 08:36 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET) - Cusabio Recently, Sanofi invested $20 million to gain priority negotiation rights for Zucara Therapeutics' novel SSTR2-targeting drug candidate ZT-01 for type 1 diabetes. ZT-01, an SSTR2 receptor antagonist, ...

Recently, Sanofiโ€™s $20M investment in ZT-01 for type 1 diabetes and Novartisโ€™s $745M deal for SSTR2 radiotherapeutics both point to one thing: SSTR2 is emerging as a key target in modern drug development.

๐Ÿ‘‰ Read more: bit.ly/4a1Dlw2

16.01.2025 01:12 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

Dr. Lola Zerbib and her team highlight alpelisib, a PI3Kฮฑ inhibitor, as a breakthrough for #PIK3CA/TEK-related #VenousMalformations, reducing lesions by 33.4% (PIK3CA) and 27.8% (TEK) in therapy-resistant patients.
Learn more: www.nature.com/articles/s41...

14.01.2025 01:25 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

๐ŸŽ‰ As we celebrate CUSABIOโ€™s 17th Anniversary, we invite you to share your story with us!

๐Ÿ“… Submission Deadline: February 15, 2025
๐ŸŽ ๐Ÿ๐ŸŽ๐ŸŽ% ๐–๐ข๐ง ๐‘๐š๐ญ๐ž: Every approved story wins a prize!

๐Ÿ‘‰ Celebrate with us: bit.ly/3Dnp1BH

#CUSABIO17 #Anniversary #Research #ShareYourStory

13.01.2025 06:38 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
DDR1; Tumor Therapy; TME DDR1 has been newly identified as a member of the receptor tyrosine kinases (RTKs) family. It is widely recognized that RTKs control cell proliferation and differentiation, which are involved in tumor...

DDR1 plays key roles in cell proliferation, migration & tumor invasion. Recent research highlights its role in forming a barrier that blocks T cells, helping tumors evade immunity. Inhibiting DDR1 could restore immune cell activity, offering exciting potential for cancer treatment. bit.ly/4iUp7Ry

06.01.2025 01:26 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Video thumbnail

๐‡๐ž๐ฅ๐ฅ๐จ, ๐๐ฅ๐ฎ๐ž๐ฌ๐ค๐ฒ! ๐ŸŒŸ

Weโ€™re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. ๐Ÿงช

โ€œ๐’€๐’๐’–๐’“ ๐’ˆ๐’๐’๐’… ๐’‘๐’‚๐’“๐’•๐’๐’†๐’“ ๐’Š๐’ ๐’ƒ๐’Š๐’๐’๐’๐’ˆ๐’š ๐’“๐’†๐’”๐’†๐’‚๐’“๐’„๐’‰.โ€

Follow us for updates and collaboration opportunities!

03.01.2025 09:31 โ€” ๐Ÿ‘ 3    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

@cusabio is following 20 prominent accounts